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Abstract 
Context: The management of congenital hyperinsulinism (CHI) has improved.
Objective: To examine the treatment and long-term outcome of Finnish patients with 
persistent and transient CHI (P-CHI and T-CHI).
Design: A population-based retrospective study of CHI patients treated from 1972 to 
2015.
Patients: 106 patients with P-CHI and 132 patients with T-CHI (in total, 42 diagnosed 
before and 196 after year 2000) with median follow-up durations of 12.5 and 6.2 years, 
respectively.
Main Outcome Measures: Recovery, diabetes, pancreatic exocrine dysfunction, 
neurodevelopment.
Results: The overall incidence of CHI (n = 238) was 1:11 300 live births (1972-2015). From 
2000 to 2015, the incidence of P-CHI (n = 69) was 1:13 500 and of T-CHI (n = 127) 1:7400 
live births. In the 21st century P-CHI group, hyperinsulinemic medication was initiated 
and normoglycemia achieved faster relative to earlier. Of the 74 medically treated P-CHI 
patients, 68% had discontinued medication. Thirteen (12%) P-CHI patients had partial 
pancreatic resection and 19 (18%) underwent near-total pancreatectomy. Of these, 
0% and 84% developed diabetes and 23% and 58% had clinical pancreatic exocrine 
dysfunction, respectively. Mild neurological difficulties (21% vs 16%, respectively) and 
intellectual disability (9% vs 5%, respectively) were as common in the P-CHI and T-CHI 
groups. However, the 21st century P-CHI patients had significantly more frequent normal 
neurodevelopment and significantly more infrequent diabetes and pancreatic exocrine 
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Conclusions: Our results demonstrated improved treatment and long-term outcome in 
the 21st century P-CHI patients relative to earlier.
Key Words: hypoglycemia, neurodevelopment, pancreatic exocrine dysfunction, diabetes, recovery
Congenital hyperinsulinism (CHI) is a rare disease that is 
characterized by inappropriate insulin secretion resulting 
in hypoglycemia, typically in neonates or young children 
(1). CHI comprises of a heterogenous group of disorders 
with diverse etiologies and clinical features (2). Persistent 
CHI (P-CHI) is considered to be a monogenic disease with 
an estimated incidence of 1:27 000 to 1:50 000 live births 
in different populations (3-5). CHI-associated mutations 
have been identified in at least 14 genes, most commonly 
in ABCC8 or KCNJ11 encoding the subunits of the KATP 
channels in the pancreatic beta cell (6). In Finland, the 2 
founder variants, recessive ABCC8/p.V187D (7) and dom-
inant ABCC8/p.E1506K (8), previously accounted for 88% 
of the mutation-positive patients (9). The more common 
transient hyperinsulinism (T-CHI) typically associates with 
pre- or perinatal conditions, such as maternal gestational 
diabetes, small birth size, or birth asphyxia (10). In addition, 
hyperinsulinism may appear as part of syndromic genetic 
disorders, such as Beckwith-Wiedemann syndrome (11).
CHI and its treatment may have significant long-term 
effects on the patients. Nonketotic hypoglycemia leads to 
a high risk of neurological impairment by blocking the 
formation of alternative energy sources, ie, ketone bodies, 
during hypoglycemia (12). Abnormal neurodevelopment 
has been reported in 26% to 48% of patients with P-CHI 
(12-16) and in 25% to 30% of patients with T-CHI (12, 16, 
17). Moreover, nearly all patients have developed insulin-
dependent diabetes after a near-total pancreatectomy (18, 
19) which also leads to a high risk of pancreatic exocrine 
dysfunction (19, 20).
In the 21st century, the increased understanding of the 
pathophysiological mechanisms of CHI has improved the 
awareness of the disease and led to more individualized 
treatment according to drug response and genetic findings 
(21), compared to the former recommendations of an early 
radical pancreatectomy. Currently, genetic information 
and noninvasive [18]F-fluoro-L-dihydroxyphenylalanine 
(18F-DOPA) positron emission tomography (PET) scan 
can be used to identify patients with focal CHI, which is 
caused by a combination of paternally inherited mutation 
and maternal somatic loss of heterozygosity in the affected 
cells and is curable by partial pancreatic resection (21-23). 
These patients are typically diazoxide-unresponsive and 
hence, radical pancreatectomy was the former choice of 
treatment for many of them. Diffuse CHI caused by re-
cessive biallelic KATP mutations associating with the most 
severe phenotypes may still necessitate near-total pancrea-
tectomy to avoid hypoglycemic brain damage, but medical 
treatment is usually effective in other genotypes causing 
diffuse CHI. Moreover, some patients who are unrespon-
sive to first-line diazoxide drug therapy can be treated with 
second-line octreotide. (21-23) At present, it is unclear 
whether the improvements in management of CHI have af-
fected the long-term outcome (12, 24-26).
In the current study, we examined the clinical charac-
teristics, treatment, and long-term outcome of P-CHI and 




This retrospective study cohort included 238 patients with 
P-CHI (n = 106) or T-CHI (n = 132) who were identified 
by a diagnosis-based search from the patient records of 
the 19 largest hospitals in Finland from the period 1972 
to 2015. As it is unlikely that CHI would have been diag-
nosed outside these hospitals, the register is representative 
for Finland. The median follow-up durations in the P-CHI 
and T-CHI groups were 12.5 years (3 months to 43 years) 
and 6.2 years (1 week to 19 years), respectively. The pa-
tients with P-CHI and T-CHI were from 93 and 132 dif-
ferent families, respectively. All patients were of Finnish 
ethnicity, except for 5 children in the P-CHI group.
The inclusion criteria were the diagnosis of CHI 
based on a combination of prolonged or recurrent 
hypoglycemia and signs of inappropriate insulin secre-
tion: detectable serum insulin level and/or low free fatty 
acids during nonketotic hypoglycemia. Only patients 
who needed medication for hyperinsulinism (diazoxide 
or octreotide) were included. The definition of hypo-
glycemia was based on the recommendations of the 
Pediatric Endocrine Society: plasma glucose concentra-
tion ≤2.8 mmol/L (≤50 mg/dL) in the first 48 hours of 
life, and ≤3.3 mmol/L (≤60 mg/dL) thereafter (27). The 
routine screening of neonatal hypoglycemia referred to 
routine measurements of blood glucose within the 2 days 
after birth in newborns at risk.
The data were collected from the medical records by 
one of the authors (J.M.). We classified the patients retro-
spectively into the T-CHI group, when hyperinsulinism 
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birth) and medication was successfully discontinued within 
the first 4 months with no evidence of recurrent hypogly-
cemia during or after medication. All other patients were 
considered to have P-CHI. The specific genetic data was 
available for 95 and 58 patients with P-CHI and T-CHI, 
respectively, who were included in our previous genetic 
study by exon sequencing of 104 genes affecting glucose 
metabolism, including 10 CHI-associated genes (ABCC8, 
KCNJ11, GLUD1, GCK, HNF4A, HNF1A, SLC16A1, 
HADH, UCP2, and HK1) (28). With respect to the longi-
tudinal comparisons, the year 2000 was chosen as a cutoff 
point on the basis of markedly increased awareness of CHI 
due to the identification of the 2 Finnish founder variants 
by that time (7, 29).
Severe symptoms at onset referred to seizures or coma, 
and mild symptoms to any other hypoglycemia-related symp-
toms. Hyperinsulinemic medication referred to diazoxide or 
octreotide. Responsiveness to diazoxide was defined clinic-
ally, when an asymptomatic child had normal blood glucose 
levels and did not need intravenous (IV) glucose infusion. 
Recovery from CHI was defined clinically when normo-
glycemia sustained at the withdrawal of hyperinsulinemic 
medication according to repeated blood glucose measure-
ments by fingerprick tests or continuous tissue glucose 
monitoring. Near-total pancreatectomy referred to ≥90% 
resection of pancreas for presumed diffuse CHI.
Neurodevelopmental outcome was divided into 3 
groups. “Normal development” was considered when no 
signs of developmental problems were documented and the 
child attended mainstream school. “Mild difficulties” in-
cluded a reported diagnosis of pervasive or specific develop-
mental disorder (ICD-10 codes F80, Specific developmental 
disorders of speech and language; F81, Specific devel-
opmental disorders of scholastic skills; F82 Specific de-
velopmental disorders of motor function; F84 Pervasive 
developmental disorders; and F88 Other disorders of psy-
chological development; F89 Unspecified disorder of psy-
chological development), or a need for educational or 
developmental (occupational, speech or physiotherapy) 
support. “Intellectual disability” was defined as documented 
IQ < 70 (ICD-10 definition of intellectual disability, ICD-10 
codes F70-F79 for intellectual disability of varying severity).
Statistical Analysis
All statistical analyses were performed using SPSS ver-
sion 22.0 (SPSS Inc., Chicago, IL, USA). Differences be-
tween continuous variables were analyzed using the 
nonparametric Mann-Whitney U test. The chi-square and 
Fisher exact tests were used to test for the associations be-
tween categorical variables. P < 0.05 was considered statis-
tically significant.
Ethical Considerations
The study was approved by the local Research Ethics 
Committee of the Nothern Savo Hospital District and it 
was conducted in accordance with the Helsinki Declaration.
Results
Clinical Characteristics
The clinical characteristics are presented in Table 1. In 
P-CHI and T-CHI groups, the median gestational ages were 
Table 1. Clinical Characteristics of the Patients With Congenital Hyperinsulinism (n = 238)
P-CHI, all  
(n = 106)
T-CHI, all  
(n = 132)
P P-CHI, before 
the 21st century 
(n = 37)
P-CHI, in the  
21st century  
(n = 69)
P
Gender M / F (%) 53% / 47% 64% / 36% 0.085 54% / 46% 52% / 48% 1.000
Preterm, born before 37 weeks of pregnancy, % (n) 23.6% (25) 40.2% (53) 0.017 35.1% (13) 17.4% (12) 0.052
Small for gestational age, (<-2 SDS), % (n) 9.4% (10) 34.8% (46) <0.001 2.7% (1) 13.0% (9) 0.159
Large for gestational age, (>2 SDS), % (n) 27.4% (29) 10.6% (14) 0.001 37.8% (14) 21.7% (15) 0.105
Neonatal onset of hypoglycemia, % (n) 70.8% (75) NA NA 73.0% (27) 69.6% (48) 1.000
Severe symptoms at detection of hypoglycemia, % (n) 21.7% (23) 0.8% (1) <0.001 37.8% (14) 13.0% (9) 0.007
Hypoglycemia detected in routine blood glucose 
screening, % (n)a
28.3% (30) 49.2% (65) 0.002 16.2% (6) 34.8% (24) 0.038
CHI-associated gene variant, % (n)b 60.0% (64) 0.0% (0) <0.001 73.0% (27) 56.9% (37) 0.194
Syndrome-related CHI, % (n) 7.5% (8) 5.3% (7) 0.592 0.0% (0) 12.1% (8) 0.076
Fisher exact test was used.
Abbreviations: P-CHI, persistent CHI; T-CHI, transient CHI; SDS, standard deviation score.








ational Library of H
ealth Sciences user on 28 June 2021
The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 4 e1545
38.4 (range, 27.1-42.1) weeks and 37.5 (24.0-41.9) weeks, 
respectively. The median birth weight standard deviation 
scores (SDS) in the P-CHI and T-CHI groups were 0.8 SDS 
(−3.3 to 7.2 SDS) and −1.3 SDS (−4.3 to 4.6 SDS) and the 
median birth weights 3800 g (range, 1020 to 5360 g) and 
2680 g (520 to 5100 g), respectively.
The patients with P-CHI (n = 106) were more often 
born large for gestational age, whereas the patients with 
T-CHI (n = 132) were more often born small for gestational 
age or preterm (<37 gestational weeks).
Genetic syndromes were equally common in both 
groups. Trisomy 21 was diagnosed in altogether 5 (2.1%) 
patients (3 with P-CHI, 2 with T-CHI). Hence, it was signifi-
cantly more common in this cohort (1:50) compared with 
the expected incidence in Finland (1:870) (30) (P < 0.001). 
Additionally, 5 patients had Beckwith-Wiedemann syn-
drome (2 with P-CHI, 3 with T-CHI), 1 had trisomy 13, 
2 Turner mosaicism (1 with P-CHI, 1 with T-CHI), and 1 
triploid mosaicism.
Genetics
We have previously reported the genetic findings of 95 
and 58 patients in this cohort with P-CHI and T-CHI, re-
spectively, based on exon sequencing of 10 CHI-associated 
genes (28). As a summary of the previous results, patho-
genic or likely pathogenic gene variants were identified in 
68% of the patients with P-CHI. KATP channel genes ex-
plained the disease in 56% (n = 53) of all P-CHI patients 
(5 patients with homozygous recessive, 6 with compound 
heterozygous recessive, 15 with heterozygous recessive 
founder mutation ABCC8/p.V187D, 14 with heterozygous 
dominant founder mutation ABCC8/p.E1506K, 3 with 
other heterozygous dominant variants, 6 with other het-
erozygous recessive variants, and 4 with a novel heterozy-
gous variants having yet undetermined inheritance). The 
2 founder mutations accounted for 58% (n = 38) of the 
mutation-positive patients. Additionally, 13% (n = 12) of 
the P-CHI patients carried a pathogenic or likely patho-
genic variant in other CHI-associated genes, (including 
heterozygous dominant variants in GLUD1, n = 6; GCK, 
n = 2; SLC16A1, n = 3; and HNF4A, n = 1). None of the 
patients with T-CHI carried a CHI-causing gene variant.
Diagnosis
The diagnostic features are presented in Table 1. In P-CHI 
group, hypoglycemia was detected in the neonatal period 
(aged < 28 days), infancy (28 days to 1 year), and in child-
hood (>1 years) in 71%, 22%, and 7%, respectively, of the 
patients with P-CHI.
Hypoglycemia was significantly more often diagnosed 
in routine screening of neonatal hypoglycemia in the 
T-CHI than in P-CHI group (P = 0.002), but also in the 
21st century P-CHI patients compared with the earlier 
patients (P = 0.038). Severe symptoms at the onset were 
significantly more common in the P-CHI group than the 
T-CHI group (P < 0.001), and more infrequent in the more 
recently treated P-CHI patients (P = 0.007). Severe symp-
toms at the onset were significantly more common when 
hypoglycemia manifested at a post-neonatal age compared 
with the neonatal period (61% vs 8%; P < 0.001).
Incidence
During the 44-year study period, the overall incidence of 
CHI (n = 238) was 1:11 300 live births and the incidence 
of P-CHI was 1:25 400 live births (Fig. 1). The incidence 
of P-CHI was 1:47 600 from 1972 to 1999 (n = 37) and 
1:13 500 live births from 2000 to 2015 (n = 69), respect-
ively. The first documents of hyperinsulinism which we clas-
sified as T-CHI were from 1996. Between 2000 and 2015, 
the incidence of T-CHI was 1:7400 live births (n = 127).
Treatment and Clinical Outcome
The details of treatment are presented in Table 2. In the 
P-CHI group, hyperinsulinemic medication was started at 
the median age of 16  days (range, 1  day to 11.3  years). 
Hyperinsulinemic medication was started and IV glucose 
infusion stopped significantly earlier in the 21st century 
P-CHI group compared with the P-CHI patients treated 
earlier (Table 2). There was no difference in the maximal 
glucose infusion rate between the P-CHI and T-CHI groups 
(P > 0.05).
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Initially, 68% (n = 66) of the patients with P-CHI were 
diazoxide-responsive. Altogether, 70% (n = 74) of the 
P-CHI patients were treated medically (64 with diazoxide, 
10 with octreotide), including also 1 patient with presumed 
focal CHI and 1 with a pathogenic compound heterozy-
gous ABCC8 variant (Fig. 2).
Thirty-two (30%) P-CHI patients underwent an oper-
ation. Of these, 13 patients had partial resection of pan-
creas for a suspected focal or multifocal disease at the 
median age of 4 months (range, 1 week to 16 months), ran-
ging from excision of a 5-mm lesion to 80% pancreatec-
tomy. The other 19 patients underwent near-total (≥90%) 
pancreatectomy for a presumed diffuse CHI at the median 
age of 1 month (range, 1 week to 3.5 years), including all 
except for 1 patient with homozygous or compound het-
erozygous KATP variant. Near-total pancreatectomy was not 
performed after year 1996, which was related to the fact 
that there were no patients with biallelic KATP variants.
In the T-CHI group, medication was started at the me-
dian age of 7 days (range, 1 to 102 days). All patients were 
diazoxide-responsive, when used, and 1 patient was treated 
with octreotide. The maximal diazoxide dose was signifi-
cantly lower in T-CHI group compared with the P-CHI 
group (P < 0.001) (Table 2).
Long-Term Outcome: Recovery in P-CHI Group
Of the medically treated P-CHI patients, 68% (50 of 
74)  had discontinued medication (79% of the patients 
aged over 4 years [48 of 61]), the median duration of drug 
treatment being 3.3 years (range, 2 months to 20.2 years) 
(Fig. 3). The frequency of the recovered patients managing 
without medication did not differ between patients with or 
without an identified CHI gene variant (P > 0.05).
Twelve of the 13 patients having partial pancreatic re-
section were confirmed to have focal CHI and did not need 
hyperinsulinemic medication after partial pancreas resection, 
while 1 patient most likely had a diffuse disease (a slightly 
higher local activity detected by 18F-DOPA-PET turned out 
to arise from a lymph node). Near-total pancreatectomy 
had variable effect on hyperinsulinism. Twelve (63%) of 
the 19 patients did not ever again need hyperinsulinemic 
medication, 5 patients (26%) needed an intermittent period 
of medication for recurrent hypoglycemia manifesting after 
1  month to 2.5  years postsurgically, 1 patient (5%) was 
manageable with hyperinsulinemic medication, which con-
tinued immediately after the surgery, and 1 patient (5%) 
needed total pancreatectomy as a second operation.
Long-Term Outcome: Diabetes and Pancreatic 
Exocrine Dysfunction
After ≥90% pancreatectomy, 16 of 19 (84%) patients de-
veloped insulin-dependent diabetes at the median age 
of 5.7  years (range, 0 to 20.8  years) (Table 3). The me-
dian latest blood glycated hemoglobin (HbA1c) level was 
Table 2. Treatment of Patients With Congenital Hyperinsulinism (n = 238)




P P-CHI, before 
the 21st century 
(n = 37)




IV glucose, duration (d)a 12 (2-75) 6 (0-26) <0.001c 22 (3-46) 8 (2-75) 0.003c
IV glucose, maximal rate (mg/kg/min)a 12.8 (4.0-25.9) 12.6 (1.9-20.0) 0.581c 14.1 (5.5-25.9) 12.0 (4.0-21.0) 0.505c
Time between the first hypoglycemia  
and initiation of hyperinsulinemic 
medication, (d)b
10 (0-3926) 6 (0-97) 0.012c 19 (1-3926) 6 (0-78) 0.010c
Diazoxide, maximal dose (mg/kg/d) 10.5 (3.3-34.0) 9.5 (2.1-20.1) <0.001c 11.3 (3.8-34.0) 10.3 (3.3-21.0) 0.523c
Current medication, % (n) 22.4% (24) NA NA 13.5% (5) 27.1% (19) NA
Partial pancreas resection, % (n) 12.3% (13) NA NA 2.7% (1) 17.4% (12) 0.030d
≥90% pancreatectomy, % (n) 17.0% (19) NA NA 51.4% (19) 0 (0) <0.001d
Continuous variables are presented as median (range) values.
Abbreviations: d, day(s); P-CHI, persistent CHI; T-CHI, transient CHI.
aIn neonates; bhyperinsulinemic medication referring to diazoxide or octreotide; cMann-Whitney U test; dFisher exact test.
Figure 2. Treatment methods in patients with persistent congenital 
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75 mmol/mol (56 to 99 mmol/mol) at the median duration 
of diabetes of 16.8 years (1.6 to 23.8 years). None of the 
medically treated patients or P-CHI patients having par-
tial pancreatic resection had diabetes. Clinical pancreatic 
exocrine dysfunction (ie, need for enzyme supplements) 
was found in 3 (23%) and 11 (58%) patients after partial 
resection and near-total pancreatectomy, respectively, and 
in none of the patients with T-CHI.
These 2 major comorbidities were significantly more un-
common in the 21st century P-CHI patients compared with 
the earlier patients, obviously because near-total pancrea-
tectomies were not performed (Tables 2 and 3).
Figure 3. The frequencies of P-CHI patients who were able to discontinue hyperinsulinemic medication A) in medical treatment, B) after partial pan-
creatic resection for suspected focal CHI, and C) after near-total pancreatectomy for presumed diffuse CHI.
Table 3. The Long-Term Outcome in Patients With Congenital Hyperinsulinism (n = 238)
P-CHI, all  
n = 106
T-CHI, all  
n = 132
P P-CHI, before 
the 21st century 
(n = 37)




Complete recovery, % (n) 77.4% (82) NA NA 86.5% (32) 72.5% (50) NA
Normal development, all % (n) 69.8% (74) 79.5% (105) 0.100 48.6% (18) 81.2% (56) 0.001
 Normal development, isolated CHI, % (n)a 75.0% (63) 90.2% (83) 0.009 51.6% (16) 88.7% (47) <0.001
Mild developmental difficulties, all % (n) 20.8% (22) 15.9% (21) 0.400 35.1% (13) 13.0% (9) 0.011
 Mild difficulties, isolated CHI, % (n)a 20.2% (17) 9.8% (9) 0.058 35.5% (11) 11.3% (6) 0.011
Intellectual disability, all % (n) 8.5% (9) 4.5% (6) 0.192 16.2% (6) 5.8% (4) 0.094
 Intellectual disability, isolated CHI, % (n)a 4.8% (4) 0.0% (0) 0.050 12.9% (4) 0.0% (0) 0.016
Epilepsy, % (n) 15.1% (16) 3.0% (4) 0.002 32.4% (12) 5.8% (4) 0.001
 Epilepsy, isolated CHI, % (n)a 14.3% (12) 0.0% (0) <0.001 35.5% (11) 1.9% (1) <0.001
Diabetes, % (n) 15.1% (16) 0.0% (0) <0.001 43.2% (16) 0.0% (0) <0.001
Clinical pancreatic exocrine dysfunction, % (n) 13.2% (14) 0.0% (0) <0.001 29.7% (11) 4.3% (3) <0.001
Fisher exact test was used.
Abbreviations: CHI, congenital hyperinsulinism; P-CHI, persistent CHI; T-CHI, transient CHI.
aIn patients without other potential factors disturbing neurodevelopment than hyperinsulinism; P-CHI all, n = 84; T-CHI all, n = 92; P-CHI before 21st century, 
n = 31; P-CHI in the 21st century, n = 53; (excluded patients with prematurity <32 gestational weeks, severe birth asphyxia, grade 2-4 intraventricular hemor-
rhage, brain abnormality or damage due to other reasons, a neurological disorder or a syndrome potentially affecting the development, and inadequate data for 
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Long-Term Outcome: Neurodevelopment
The P-CHI patients treated in the 21st century had signifi-
cantly more often normal neurodevelopment (P = 0.001), 
and significantly less frequently mild developmental diffi-
culties (P = 0.011) and epilepsy (P = 0.001) compared with 
the P-CHI patients treated earlier (Table 3). The neuro-
logical outcome did not statistically differ between the 
P-CHI and T-CHI groups, except for that epilepsy was sig-
nificantly more common in the P-CHI group (P = 0.002).
Mild neurodevelopmental difficulties were equally 
common in patients treated with near-total pancreatectomy 
(6 of 19) and partial pancreatic resection (5 of 13) (32% 
vs 38%, respectively), but intellectual disability was diag-
nosed only in the pancreatectomy group (3 of 19) (16% vs 
0%, respectively).
To more specifically evaluate the hypoglycemic 
effect, we further analyzed the neurological outcome 
in a selected group of patients without other factors 
potentially affecting neurodevelopment: prematurity 
(<32 gestational weeks), severe birth asphyxia, grade 
2 to 4 intraventricular hemorrhage, brain abnormality 
or damage due to other reasons, or a neurological dis-
order or syndrome potentially affecting development. 
Altogether, 22 (20.8%) P-CHI patients and 40 (30.3%) 
T-CHI patients were excluded. The proportions of nor-
mally developed children (P-CHI, 75% and T-CHI, 90%) 
were higher in patients having an isolated CHI as com-
pared with the unselected groups (P-CHI, 70% and 
T-CHI, 80%) (Table 3).
Six patients died for several reasons. Severe 
hyperinsulinism was the main cause of death in 1 trisomy 
21 patient with a pathogenic heterozygous KCNJ1 variant 
and a contributing factor for death in 1 adult patient 
having a severe heterozygous GCK variant (31). CHI was 
not denoted to contribute to the death in 1 patient with 
the recessive founder mutation ABCC8/p.V187D or in the 
other 3 mutation-negative patients.
Associating Factors for Adverse 
Neurological Outcome
The P-CHI patients with abnormal neurodevelopment 
had significantly longer duration of IV glucose (20 vs 
8  days; P = 0.001) and time before the initiation of 
hyperinsulinemic medication after the detection of hypo-
glycemia (14 vs 7 days; P = 0.022) as well as significantly 
more commonly severe symptoms at the onset (38% vs 
18%; P = 0.041) and surgical treatment (41% vs 24%; 
P = 0.040) compared with the P-CHI patients with normal 
neurodevelopment.
In the T-CHI group, abnormal neurodevelopment asso-
ciated with a longer time between the first detected hypo-
glycemia and initiation of hyperinsulinemic medication (8 
vs 6  days; P = 0.032). Abnormal neurodevelopment was 
not associated with birth size, gestational weeks at birth, 
having symptoms at the onset of hypoglycemia or not, the 
maximal rate of IV glucose, or maximal dose of diazoxide 
in either group.
Discussion
We examined the diagnosis, treatment, and long-term out-
come of CHI patients in a national retrospective cohort 
from a 44-year period, focusing on a longitudinal perspec-
tive. Long-term outcome of P-CHI has improved in re-
spect of pancreatic endocrine and exocrine function, since 
all the diazoxide-unresponsive patients avoided near-total 
pancreatectomy due to having focal CHI or adequate re-
sponse to octreotide. Furthermore, the neurological out-
come was more favorable in more recently treated P-CHI 
patients, which is attributable to the faster achievement 
of normoglycemia and increased diagnosis of also milder 
CHI. However, the risk of adverse neurological outcome 
is still high in both P-CHI and T-CHI, especially when 
manifesting with other factors potentially disturbing 
neurodevelopment.
Typically, diazoxide-responsive dominant CHI was 
more common in this study (27% of P-CHI patients) 
compared with other cohorts (20% to 21%) (6, 32) due 
to the Finnish founder mutation ABCC8/p.E1506K (8). 
However, the other founder mutation, recessive ABCC8/p.
V187D manifested frequently as biallelic or focal CHI 
causing diazoxide-unresponsive disease (28). Diazoxide-
responsiveness (68%) was markedly higher compared 
to the largest cohort at present from Philadelphia in the 
United States (39%) (6) but did not differ from 2 other 
previous large studies (61% to 68%) (32, 33). This differ-
ence between the studies could be explained by a selection 
of more severe patients referred to the Philadelphia center, 
especially regarding focal CHI, which was more common 
in their study (31%) compared with ours and the 2 other 
studies (6% to 11%) (32, 33)
The proportion of the medically treated P-CHI patients 
who were able to discontinue medication (68%) fell be-
tween 61% (33) and 95% (34) reported by previous studies 
(both calculated from their data, excluding patients who 
we would have classified as having T-CHI) Although the 
study designs in these 3 cohorts were different, these find-
ings indicate a high probability of spontaneous remission of 
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age, but sometimes even in adulthood. The similar recovery 
frequency in mutation-positive and mutation-negative 
groups in the current study likely reflects the relatively high 
number of dominant CHI variants.
Interestingly, medical treatment was successful also in 
2 P-CHI patients with presumed focal or multifocal le-
sions. In these patients, the severity of the disease and the 
focal signal detected by 18F-DOPA-PET scan decreased 
during the follow-up and medication was discontinued 
(ages 7  months and 4  years). This self-limiting nature of 
focal P-CHI, also reported in a previous study (35), might 
possibly be explained by an increased apoptosis rate in the 
mutant beta cells (36). Furthermore, as we have previously 
reported (28), 1 patient with pathogenic compound hetero-
zygous KATP variant and several carriers of a heterozygous 
missense KATP variant were treated with diazoxide.
As expected based on previous studies, partial pancre-
atic resection was curative in all patients with subsequently 
confirmed focal CHI (18, 23, 37-40) and none of these de-
veloped diabetes (18, 40). Notably, 3 patients developed 
pancreatic exocrine dysfunction 4 months to 8 years after 
a 50% to 80% resection of the pancreas after combined 
with Roux-en-Y, which is a common risk factor for this 
comorbidity (41). This contradicts a previous large clin-
ical study which indicated normal exocrine function after 
partial pancreatic resection and Roux-en-Y (38), a longer 
follow-up period in the current study only partly explains 
this difference.
This study demonstrated the presumed (15) decrease 
in the prevalence of diabetes and pancreatic exocrine dys-
function over time, since the identification of those having 
focal CHI among other diazoxide-unresponsive patients has 
markedly decreased the need for radical pancreatectomy. 
Moreover, near-total pancreatectomy was not needed in 
Finland in the 21st century, since there were no cases with 
homozygous (and only 1 with compound heterozygous) 
KATP gene mutations associating with the most severe pheno-
types (28). The results are gratifying, considering that the 
prevalence of diabetes (84%) and clinical pancreatic exo-
crine dysfunction (58%) after near-total pancreatectomy 
were high, consistent with previous studies (56% to 96% 
(18, 19, 24, 42) and 39% to 63% (19, 37, 43), respectively).
The current study also showed that P-CHI patients 
treated in the 21st century had better neurological outcome 
compared to previously treated patients. This explains the 
lower overall frequency of abnormal neurodevelopment in 
P-CHI (29%) compared to the other nationwide studies 
from (44% to 45%) (15, 44). Longitudinal improvement 
in the outcome has not emerged in previous studies (12, 
24-26), except for one small cohort (n = 14) (45). The lack 
of the most severe phenotypes may have contributed to 
the results, but also our findings of increased detection of 
hypoglycemia before symptoms (by the advanced routine 
blood glucose screening in newborns at risk), as well as 
earlier diagnosis of hyperinsulinism and achievement of 
normoglycemia are attributable to the improved prognosis.
Despite the improvements, the current frequencies of 
abnormal neurodevelopment and epilepsy were still high 
and strengthened the previous findings of similar outcome 
in T-CHI and P-CHI (12, 17). However, hypoglycemia may 
not be the only determinant of the outcome (15, 46). We 
found that CHI manifested frequently in association of 
other factors potentially affecting the development (P-CHI 
22%; T-CHI 30%), which may even further worsen the 
outcome. Interestingly, the prevalence of Down syndrome 
was surprisingly high, although it has not been previously 
reported to associate with hyperinsulinism. Encouragingly, 
however, the T-CHI patients and the 21st century P-CHI 
patients having an isolated CHI showed similar propor-
tions of normal development as the general population and 
none had intellectual disability.
Nevertheless, the high risk of even mild neurological 
impairment in this potentially fatal disease is to be taken 
seriously. In our previous clinical study, the 21st century 
P-CHI patients without any other risk factors than hypo-
glycemia (a subcohort of the current study) showed narrow 
specific neurocognitive problems eligible for hypoglycemic 
origin in (16). The current study strengthened the previous 
observations of the association of more severe disease or 
delay in treatment with poorer neurological outcome (12, 
15, 25, 44, 47, 48) and hence, timely diagnosis and effi-
cient treatment are most important in the pursuit of better 
outcome.
The incidence of P-CHI (1:25  400 live births) was 
surprisingly high compared to the previous estimates 
(1:27  000 to 1:50  000 live births) (3, 5, 49). The inci-
dence of T-CHI, 1:7400 live births between 2000 and 
2015, was also higher compared to the previous 2 esti-
mates of 1:12  000 to 1:17  000 live births (49, 50), al-
though comparisons between studies are difficult because 
the definition of T-CHI is not generally well established. 
The current incidence suggests that hyperinsulinism is 
the cause in 1 per 7 to 25 newborns with hypoglycemia 
(incidence of neonatal hypoglycemia, 1-3.5:1000). Our 
population-based, more recent study cohort and more ac-
curate documentation of diagnosis and improved protocol 
of screening of blood glucose in newborns at risk have 
most likely contributed to the increased incidence in the 
early 2000s, especially regarding T-CHI. Nevertheless, it 
cannot be ruled out that CHI is more common in Finland 
due to its genetic isolation and founder effects (49, 50).
This study has some limitations. As discussed above, it 
is likely that the diagnosis search did not capture all the 
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of ICD-10 in 1996 which provides a more specific code 
for hyperinsulinism. Moreover, the patients did not usually 
undergo a formal fasting test at the time of discontinuation 
of medication, which may slightly overestimate the propor-
tion of the patients classified as “recovered.” Furthermore, 
there was no uniform protocol for the clinical follow-up 
of the patients, but it was planned individually and hence, 
referral bias cannot be excluded regarding pancreatic exo-
crine dysfunction and milder neurological difficulties.
In conclusion, this retrospective nationwide study cohort 
demonstrated an improved overall long-term outcome of 
P-CHI patients over time. This is attributable to the faster 
recognition of hyperinsulinism, more prompt achievement 
of normoglycemia, and more individualized treatment of 
CHI. Notably, both P-CHI and T-CHI commonly occurred 
in combination with other conditions potentially disturbing 
neurodevelopment, but the neurological outcome of the pa-
tients with an isolated form of P-CHI was not strikingly 
different from the general population.
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